All In Biotech

Drug Trial Radar · NCT03182088

Norepinephrine Infusion Different Doses in Cesarean Delivery

Norepinephrine Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Dose Finding Trial.

Last checked: Nov 19, 2026Latest source record: Aug 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Jun 15, 2017

Primary completion

Dec 25, 2017

Study completion Dec 30, 2017

Sponsor

Lead sponsor
Cairo UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

three doses (0.025 mcg/Kg/min, 0.050 mcg/Kg/min, and 0.075 mcg/Kg/min) of norepinephrine will be compared for prophylaxis against Post-spinal anesthesia hypotension during Cesarean delivery.

Conditions

  • Cesarean Section Complications

Interventions

  • norepinephrine infusion (0.025 mcg/Kg/min)Drug

    The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine bitartrate infusion of (0.05 mcg/Kg/min) equivalent to norepinephrine base of (0.025 mcg/Kg/min)

  • norepinephrine infusion (0.050 mcg/Kg/min)Drug

    The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min) equivalent to norepinephrine base of (0.050 mcg/Kg/min)

  • norepinephrine infusion (0.075 mcg/Kg/min)Drug

    The patients will receive a bolus of 5 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min) equivalent to norepinephrine base of (0.075 mcg/Kg/min).

  • BupivacaineDrug

    The patient will receive spinal anesthesia using Bupivacaine (10 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. postspinal hypotensionTime frame: 30 minutes after spinal anesthesia

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cairo University

    Cairo, Egypt

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.